Biohaven

Biohaven hopes to muscle in on Ozempic with a different type of weight loss drug
Biohaven hopes to muscle in on Ozempic with a different type of weight loss drug
BioPharma Dive
Biohaven
weightloss
Ozempic
Wegovy
Flag link:
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Flag link:
Further blow for Biohaven as FDA refuses to consider failed rare disease drug for approval
Further blow for Biohaven as FDA refuses to consider failed rare disease drug for approval
Fierce Biotech
Biohaven
FDA
troriluzole
Flag link:
NICE gives thumbs-up to Pfizer's migraine drug—but with lots of restrictions
NICE gives thumbs-up to Pfizer's migraine drug—but with lots of restrictions
Fierce Pharma
Biohaven
Pfizer
migraines
NICE
Nurtec
Vydura
Flag link:
Biohaven strikes a deal to take TYK2 drugs in a new direction
Biohaven strikes a deal to take TYK2 drugs in a new direction
BioPharma Dive
Biohaven
Pfizer
Hangzhou Highlightll
psoriasis
Flag link:
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
Endpoints
Pfizer
migraines
Royalty Pharma
Biohaven
zavegepant
Flag link:
Pfizer's Biohaven bet pays off again as migraine nasal spray wins approval
Pfizer's Biohaven bet pays off again as migraine nasal spray wins approval
BioSpace
Pfizer
Biohaven
FDA
migraines
nasal spray
zavegepant
Zavzpret
Flag link:
Biohaven looks to seize a new opportunity
Biohaven looks to seize a new opportunity
EP Vantage
Biohaven
Pfizer
BHV-7000
taldefgrobep alfa
Flag link:
Biopharma’s 5 Biggest M&A Deals of 2022
Biopharma’s 5 Biggest M&A Deals of 2022
BioSpace
M&A
Amgen
Horizon Therapeutics
Pfizer
Biohaven
Global Blood Therapeutics
Bristol Myers Squibb
Turning Point Therapeutics
ChemoCentryx
Flag link:
Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite
Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite
Fierce Biotech
Biohaven
Pfizer
funding
epilepsy
Flag link:
Pfizer’s dealmaking continues as GBT, Biohaven acquisitions close
Pfizer’s dealmaking continues as GBT, Biohaven acquisitions close
Medical Marketing and Media
Pfizer
M&A
Global Blood Therapeutics
Biohaven
Flag link:
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
Fierce Biotech
Pfizer
Biohaven
migraines
epilepsy
Flag link:
Biohaven's ALS drug fails to meet study goals
Biohaven's ALS drug fails to meet study goals
Yahoo/Reuters
Biohaven
ALS
clinical trials
troriluzole
Flag link:
Intercept, Annovis and Biohaven Advance Late Phase Trials
Intercept, Annovis and Biohaven Advance Late Phase Trials
BioSpace
Intercept Pharma NASH
Annovis
buntanetap
Parkinson's Disease
Biohaven
taldefgrobep alfa
SMA
Flag link:
How Pfizer CEO Bourla's evening call brought Biohaven back into the M&A fold
How Pfizer CEO Bourla's evening call brought Biohaven back into the M&A fold
Fierce Pharma
Pfizer
Pfizer CEOs
Albert Bourla
M&A
Biohaven
SEC
Flag link:
Biopharma takeout spend ticks up
Biopharma takeout spend ticks up
EP Vantage
M&A
biotech
Pfizer
Biohaven
Bristol Myers Squibb
Turning Point Therapeutics
GSK
Affinivax
Sierra Oncology
Halozyme Therapeutics
Antares Pharma
Flag link:
Biohaven's drug for neurological disease fails late-stage study
Biohaven's drug for neurological disease fails late-stage study
Yahoo/Reuters
Biohaven
spinocerebellar ataxia
clinical trials
troriluzole
Flag link:
Pfizer Turns to Unusual Deal Structure to Buy Biohaven Drugs
Pfizer Turns to Unusual Deal Structure to Buy Biohaven Drugs
Yahoo/Bloomberg
Pfizer
Biohaven
M&A
Flag link:
Opportunities arise for once-spurned partners
Opportunities arise for once-spurned partners
EP Vantage
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Flag link:
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
BioPharma Dive
Pfizer
M&A
Biohaven
migraines
Flag link:

Pages